|
Hypercholesterolemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this population-based case-control study, the frequencies of -911 C>A polymorphism (rs3761740) of the HMGCR gene in patients with coronary heart disease (CHD) and healthy subjects were investigated and the correlations between the different genotypes and hypercholesterolemia with cardiovascular risk factors were analyzed.
|
23933271 |
2013 |
|
Hypercholesterolemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are the most commonly prescribed therapeutic agents for treating hypercholesterolemia globally.
|
30120976 |
2018 |
|
Hypercholesterolemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pharmacotherapy is an important and effective treatment modality for hypercholesterolaemia, with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ('statins') the most commonly used class of drugs.
|
23568333 |
2013 |
|
Myopathy
|
0.370 |
GeneticVariation
|
group |
BEFREE |
Although risk factors for daptomycin-associated myopathy are poorly defined, creatine phosphokinase (CPK) monitoring and temporary discontinuation of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or "statins," has been recommended.
|
29668884 |
2018 |
|
Hypercholesterolemia, Familial
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.
|
26466344 |
2016 |
|
Hypercholesterolemia, Familial
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
We have studied the effect of lovastatin, an inhibitor of the rate-limiting enzyme in cholesterol biosynthesis (3-hydroxy-3-methylglutaryl coenzyme A reductase), alone and in combination with the bile acid sequestrant cholestyramine on lipid parameters in 30 heterozygous patients with familial hypercholesterolemia (FH) during a 20-week open trial.
|
3056429 |
1988 |
|
Hyperlipoproteinemia Type IIa
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
We have studied the effect of lovastatin, an inhibitor of the rate-limiting enzyme in cholesterol biosynthesis (3-hydroxy-3-methylglutaryl coenzyme A reductase), alone and in combination with the bile acid sequestrant cholestyramine on lipid parameters in 30 heterozygous patients with familial hypercholesterolemia (FH) during a 20-week open trial.
|
3056429 |
1988 |
|
Hyperlipoproteinemia Type IIa
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.
|
26466344 |
2016 |
|
Autoimmune Diseases
|
0.310 |
GeneticVariation
|
group |
BEFREE |
However, deletion of HMGCR specifically in T<sub>regs</sub> resulted in severe autoimmunity, suggesting that this enzyme is also essential for the maintenance of T<sub>regs</sub>.
|
28542128 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
The increased risk of type 2 diabetes noted with statins is at least partially explained by HMGCR inhibition.
|
25262344 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
The HMGCR variants were also associated with risk of T2DM, although their previously reported associations with anthropometric traits were found to be confounded.
|
30645167 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
Triglyceride-lowering alleles in LPL were associated with protection from coronary disease (approximately 40% lower odds per SD of genetically lower triglycerides) and type 2 diabetes (approximately 30% lower odds) in people above or below the median of the population distribution of LDL-C-lowering alleles at 58 independent genomic regions, HMGCR, NPC1L1, or PCSK9.
|
30326043 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
Alleles near HMGCR are associated with a higher risk of type 2 diabetes, similar to the increased incidence of new-onset diabetes associated with statin treatment in randomized clinical trials.
|
27701660 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
Importantly, we demonstrate that ScrF I polymorphism of the HMGCR gene in patients with T2DM groups is associated with significant elevation of serum VLDL-C levels.
|
17870053 |
2007 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
|
18261733 |
2008 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins) are prescribed to lower serum cholesterol levels and reduce the risk of CVD.
|
22688219 |
2013 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Statins inhibit the action of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA), which is important in the synthesis of cholesterol and essential isoprenoid intermediates, thereby lowering circulating low-density lipoprotein cholesterol (LDL), a major risk factor for cardiovascular disease (CVD).
|
29935271 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We analysed the sequence of the HMG-CoA reductase gene in DNA extracted from blood samples of 16 patients with cardiovascular disorders.
|
19187128 |
2009 |
|
Coronary heart disease
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
In this population-based case-control study, the frequencies of -911 C>A polymorphism (rs3761740) of the HMGCR gene in patients with coronary heart disease (CHD) and healthy subjects were investigated and the correlations between the different genotypes and hypercholesterolemia with cardiovascular risk factors were analyzed.
|
23933271 |
2013 |
|
Coronary heart disease
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease.
|
25084356 |
2014 |
|
Coronary heart disease
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
Triglyceride-lowering alleles in LPL were associated with protection from coronary disease (approximately 40% lower odds per SD of genetically lower triglycerides) and type 2 diabetes (approximately 30% lower odds) in people above or below the median of the population distribution of LDL-C-lowering alleles at 58 independent genomic regions, HMGCR, NPC1L1, or PCSK9.
|
30326043 |
2018 |
|
Coronary heart disease
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to assess the association in the low-density lipoprotein cholesterol reduction by atorvastatin and (TTA)n polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene in patients with coronary artery disease.
|
19067673 |
2009 |
|
Coronary heart disease
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
This suggests that both polymorphisms in the HMGCR gene may be associated with lipid and lipoprotein abnormalities in CHD in the Chinese.
|
15233402 |
2004 |
|
Coronary heart disease
|
0.190 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project.
|
21347282 |
2011 |